Ventyx Biosciences Key Executives
This section highlights Ventyx Biosciences's key executives, including their titles and compensation details.
Find Contacts at Ventyx Biosciences
(Showing 0 of )
Ventyx Biosciences Earnings
This section highlights Ventyx Biosciences's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.67 | $-0.62 |
| Read Transcript | Q2 | 2023 | 2023-08-13 | N/A | N/A |
| Read Transcript | Q1 | 2023 | 2023-05-14 | N/A | N/A |
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
$1.23
Stock Price
$87.49M
Market Cap
79
Employees
Encinitas, CA
Location
Financial Statements
Access annual & quarterly financial statements for Ventyx Biosciences, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $941.00K | $470.00K | $30.00K | $- |
| Gross Profit | $- | $-941.00K | $-470.00K | $-30.00K | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $117.00M | $175.77M | $87.74M | $58.48M | $6.37M |
| General and Administrative Expenses | $31.45M | $32.23M | $25.40M | $8.67M | $684.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $31.45M | $32.23M | $25.40M | $8.67M | $684.00K |
| Other Expenses | $- | $0 | $41.00K | $-5.45M | $-1.00K |
| Operating Expenses | $148.45M | $207.99M | $113.14M | $67.15M | $7.05M |
| Cost and Expenses | $- | $207.99M | $113.14M | $67.15M | $7.05M |
| Interest Income | $-13.42M | $15.07M | $4.67M | $78.00K | $358 |
| Interest Expense | $- | $- | $- | $99.00K | $358.00K |
| Depreciation and Amortization | $- | $158.00K | $470.00K | $30.00K | $7.05M |
| EBITDA | $-148.45M | $-207.84M | $-107.96M | $-67.12M | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-148.45M | $-207.99M | $-113.14M | $-67.15M | $-7.05M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $13.33M | $15.03M | $4.71M | $-16.60M | $-21.12M |
| Income Before Tax | $-135.12M | $-192.96M | $-108.43M | $-83.75M | $-28.17M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-470.00K | $-5.38M | $358.00K |
| Net Income | $-135.12M | $-192.96M | $-107.96M | $-78.37M | $-28.53M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.97 | $-3.30 | $-2.06 | $-1.55 | $-0.57 |
| EPS Diluted | $-1.97 | $-3.30 | $-2.06 | $-1.55 | $-0.57 |
| Weighted Average Shares Outstanding | 68.48M | 58.54M | 52.47M | 50.41M | 50.30M |
| Weighted Average Shares Outstanding Diluted | 68.48M | 58.54M | 52.47M | 50.41M | 50.30M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.08M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $316.00K | $408.00K | $403.00K | $265.00K | $139.00K | $134.00K | $150.00K | $127.00K | $103.00K | $90.00K | $16.00K | $9.00K | $4.00K | $1.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-316.00K | $-408.00K | $673.00K | $-265.00K | $-139.00K | $-134.00K | $-150.00K | $-127.00K | $-103.00K | $-90.00K | $-16.00K | $-9.00K | $-4.00K | $-1.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 62.50% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $24.82M | $30.63M | $27.80M | $33.75M | $40.32M | $49.75M | $48.56M | $35.44M | $30.18M | $25.47M | $14.68M | $17.41M | $13.82M | $10.54M | $9.51M | $24.60M | $1.31M | $1.99M | $1.53M | $1.53M |
| General and Administrative Expenses | $7.60M | $7.92M | $7.91M | $8.02M | $8.33M | $8.20M | $8.59M | $7.12M | $8.39M | $5.95M | $5.72M | $5.34M | $4.00M | $2.24M | $1.68M | $747.00K | $133.00K | $245.00K | $152.50K | $152.50K |
| Selling and Marketing Expenses | $- | $- | $-316.00K | $-408.00K | $-903.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.60M | $7.92M | $7.59M | $7.61M | $7.42M | $8.20M | $8.59M | $7.12M | $8.39M | $5.95M | $5.72M | $5.34M | $4.00M | $2.24M | $1.68M | $747.00K | $133.00K | $245.00K | $152.50K | $152.50K |
| Other Expenses | $- | $- | $-21.00K | $-31.00K | $-28.00K | $-8.00K | $-5.00K | $-1.00K | $172.00K | $958.00K | $38.00K | $15.00K | $58.00K | $13.00K | $-4.37M | $-1.15M | $- | $-1.00K | $- | $- |
| Operating Expenses | $32.42M | $38.55M | $35.40M | $41.36M | $47.74M | $57.95M | $57.15M | $42.55M | $38.57M | $31.42M | $20.40M | $22.75M | $17.83M | $12.79M | $11.19M | $25.35M | $1.44M | $2.23M | $2.10M | $2.10M |
| Cost and Expenses | $32.42M | $38.55M | $35.71M | $41.77M | $48.15M | $57.95M | $57.15M | $42.55M | $38.57M | $31.42M | $20.40M | $22.75M | $17.83M | $12.79M | $11.19M | $25.35M | $1.44M | $2.23M | $2.10M | $2.10M |
| Interest Income | $3.06M | $3.35M | $3.78M | $3.23M | $3.62M | $3.93M | $3.90M | $3.62M | $3.19M | $1.01M | $342.00K | $132.00K | $- | $- | $- | $- | $- | $- | $55.50K | $55.50K |
| Interest Expense | $- | $- | $- | $- | $3.62M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $99.00K | $153.00K | $94.00K | $- | $- |
| Depreciation and Amortization | $315.00K | $309.00K | $316.00K | $408.00K | $403.00K | $265.00K | $139.00K | $134.00K | $150.00K | $127.00K | $103.00K | $90.00K | $16.00K | $9.00K | $4.00K | $1.00K | $1.44M | $2.23M | $1.69M | $1.69M |
| EBITDA | $-32.10M | $-38.24M | $-35.40M | $-41.36M | $-49.94M | $-57.69M | $-57.01M | $-42.42M | $-35.06M | $-31.29M | $-20.30M | $-22.66M | $-17.75M | $-12.77M | $-15.55M | $-37.55M | $-1.44M | $-7.06M | $- | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4437.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-32.42M | $-38.55M | $-35.71M | $-41.77M | $-48.15M | $-57.95M | $-57.15M | $-42.55M | $-38.57M | $-31.42M | $-20.40M | $-22.75M | $-17.83M | $-12.79M | $-11.19M | $-25.35M | $-1.44M | $-2.23M | $-1.69M | $-1.69M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4474.54% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $3.07M | $3.30M | $3.76M | $3.20M | $3.59M | $3.92M | $3.89M | $3.62M | $3.36M | $958.00K | $380.00K | $15.00K | $58.00K | $13.00K | $-4.37M | $-12.30M | $-15.26M | $-4.92M | $-471.00K | $-471.00K |
| Income Before Tax | $-29.35M | $-35.25M | $-31.95M | $-38.57M | $-46.75M | $-54.03M | $-53.25M | $-38.93M | $-35.21M | $-30.46M | $-20.02M | $-22.73M | $-17.77M | $-12.77M | $-15.56M | $-37.65M | $-16.70M | $-7.16M | $-2.16M | $-2.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4345.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $364.72K | $7.79M | $-265.00K | $-3.90M | $-3.62M | $-150.00K | $-958.00K | $-342.00K | $-15.00K | $58.00K | $13.00K | $-4.37M | $-1.05M | $-1.29M | $94.00K | $-471.00K | $-471.00K |
| Net Income | $-29.35M | $-35.25M | $-31.95M | $-38.57M | $-46.75M | $-54.03M | $-53.25M | $-35.31M | $-35.06M | $-29.50M | $-20.02M | $-22.72M | $-17.77M | $-12.77M | $-15.56M | $-37.65M | $-16.70M | $-7.16M | $-2.16M | $-2.16M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -4345.07% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.43 | $-0.50 | $-0.45 | $-0.62 | $-0.79 | $-0.92 | $-0.91 | $-0.61 | $-0.62 | $-0.57 | $-0.39 | $-0.45 | $-0.38 | $-0.27 | $-0.74 | $-1.78 | $-0.79 | $-0.34 | $-1.10 | $-1.10 |
| EPS Diluted | $-0.43 | $-0.50 | $-0.45 | $-0.62 | $-0.79 | $-0.92 | $-0.91 | $-0.61 | $-0.62 | $-0.57 | $-0.39 | $-0.45 | $-0.38 | $-0.27 | $-0.74 | $-1.78 | $-0.79 | $-0.34 | $-1.10 | $-1.10 |
| Weighted Average Shares Outstanding | 68.48M | 70.67M | 70.55M | 61.83M | 59.08M | 58.88M | 58.56M | 57.64M | 56.72M | 51.67M | 50.85M | 50.59M | 47.27M | 47.27M | 21.12M | 21.12M | 21.12M | 21.12M | 1.96M | 1.96M |
| Weighted Average Shares Outstanding Diluted | 68.48M | 70.67M | 70.55M | 61.83M | 59.08M | 58.88M | 58.56M | 57.64M | 56.72M | 51.67M | 50.85M | 50.59M | 47.27M | 47.27M | 21.12M | 21.12M | 21.12M | 21.12M | 1.96M | 1.96M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.26M | $51.58M | $64.82M | $70.79M | $244.00K |
| Short Term Investments | $190.06M | $200.64M | $253.12M | $187.78M | $- |
| Cash and Short Term Investments | $217.32M | $252.22M | $356.61M | $286.72M | $244.00K |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $12.30M | $12.12M | $12.75M | $4.44M | $1.00K |
| Total Current Assets | $229.62M | $264.35M | $330.69M | $263.02M | $245.00K |
| Property Plant Equipment Net | $10.28M | $12.27M | $1.94M | $254.00K | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $38.67M | $28.15M | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $36.66M | $1.08M | $96.00K | $60.00K | $- |
| Total Non-Current Assets | $46.94M | $13.35M | $40.71M | $28.46M | $- |
| Other Assets | $- | $- | $- | $-0 | $- |
| Total Assets | $276.56M | $277.69M | $371.40M | $291.48M | $245.00K |
| Account Payables | $3.13M | $5.76M | $6.43M | $4.66M | $1.10M |
| Short Term Debt | $1.05M | $1.00M | $824.00K | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $8.59M | $15.51M | $9.10M | $7.62M | $301.00K |
| Total Current Liabilities | $12.78M | $22.27M | $16.36M | $12.28M | $1.40M |
| Long Term Debt | $9.74M | $11.51M | $1.15M | $- | $12.65M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $16.85M |
| Total Non-Current Liabilities | $9.74M | $11.51M | $1.15M | $- | $29.50M |
| Other Liabilities | $- | $- | $- | $- | $-0 |
| Total Liabilities | $22.52M | $33.77M | $17.50M | $12.28M | $30.90M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $7.00K | $6.00K | $6.00K | $5.00K | $- |
| Retained Earnings | $-554.31M | $-419.19M | $-226.22M | $-117.80M | $-32.50M |
| Accumulated Other Comprehensive Income Loss | $157.00K | $-50.00K | $-1.12M | $-58.00K | $- |
| Other Total Stockholders Equity | $808.19M | $663.15M | $581.24M | $397.05M | $1.85M |
| Total Stockholders Equity | $254.04M | $243.92M | $-226.22M | $-117.80M | $-30.65M |
| Total Equity | $254.04M | $243.92M | $-226.22M | $-117.80M | $-30.65M |
| Total Liabilities and Stockholders Equity | $276.56M | $277.69M | $-208.72M | $-105.52M | $245.00K |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $276.56M | $277.69M | $-208.72M | $-105.52M | $245.00K |
| Total Investments | $190.06M | $200.64M | $291.79M | $215.93M | $- |
| Total Debt | $10.79M | $12.51M | $1.56M | $- | $12.65M |
| Net Debt | $-16.47M | $-39.07M | $-63.26M | $-70.79M | $12.40M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $27.26M | $61.77M | $40.92M | $141.90M | $51.58M | $56.61M | $51.72M | $63.67M | $64.82M | $263.27M | $45.34M | $41.69M | $70.79M | $68.99M | $102.79M | $-244.00K | $244.00K | $-309.00K |
| Short Term Investments | $190.06M | $213.06M | $198.51M | $160.68M | $200.64M | $244.21M | $280.54M | $313.25M | $253.12M | $149.15M | $205.11M | $212.66M | $187.78M | $72.97M | $- | $488.00K | $- | $618.00K |
| Cash and Short Term Investments | $217.32M | $274.82M | $239.44M | $302.58M | $252.22M | $300.82M | $332.25M | $376.92M | $356.61M | $412.42M | $250.45M | $254.35M | $258.58M | $141.95M | $102.79M | $244.00K | $244.00K | $309.00K |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $-800.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $12.30M | $14.58M | $17.49M | $17.18M | $12.12M | $7.27M | $14.45M | $10.14M | $12.75M | $11.93M | $3.48M | $6.32M | $4.44M | $3.71M | $2.24M | $- | $1.00K | $- |
| Total Current Assets | $229.62M | $289.41M | $256.93M | $319.76M | $264.35M | $308.09M | $346.70M | $387.05M | $330.69M | $418.39M | $252.19M | $257.50M | $263.02M | $145.66M | $105.03M | $244.00K | $245.00K | $309.00K |
| Property Plant Equipment Net | $10.28M | $10.62M | $10.92M | $11.24M | $12.27M | $12.53M | $1.96M | $2.02M | $1.94M | $1.98M | $2.02M | $1.59M | $254.00K | $219.00K | $72.00K | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $-3.46M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $35.62M | $- | $41.24M | $975.00K | $975.00K | $975.00K | $- | $- | $38.67M | $- | $7.90M | $18.80M | $28.15M | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $2.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.03M | $1.07M | $102.00K | $102.00K | $1.08M | $102.00K | $102.00K | $96.00K | $96.00K | $72.00K | $72.00K | $60.00K | $60.00K | $2.83M | $816.00K | $-244.00K | $- | $-309.00K |
| Total Non-Current Assets | $46.94M | $11.69M | $52.26M | $12.32M | $13.35M | $13.61M | $2.06M | $2.12M | $40.71M | $2.06M | $9.99M | $20.45M | $28.46M | $3.05M | $888.00K | $-244.00K | $- | $-309.00K |
| Other Assets | $- | $- | $1 | $1 | $0 | $-0 | $0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $276.56M | $301.10M | $309.19M | $332.08M | $277.69M | $321.70M | $348.76M | $389.17M | $371.40M | $420.44M | $262.19M | $277.95M | $291.48M | $148.71M | $105.92M | $- | $245.00K | $- |
| Account Payables | $3.13M | $2.29M | $6.58M | $5.58M | $5.76M | $9.34M | $4.08M | $6.55M | $6.43M | $18.58M | $5.80M | $7.11M | $4.66M | $4.26M | $2.37M | $- | $1.10M | $- |
| Short Term Debt | $1.05M | $1.01M | $1.94M | $946.00K | $1.00M | $958.00K | $878.00K | $852.00K | $412.00K | $790.00K | $772.00K | $556.00K | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-386.00K | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $8.59M | $9.01M | $9.58M | $8.01M | $15.51M | $15.91M | $15.07M | $9.11M | $9.51M | $16.29M | $11.10M | $10.12M | $7.62M | $7.55M | $5.69M | $- | $301.00K | $- |
| Total Current Liabilities | $12.78M | $12.30M | $18.10M | $14.53M | $22.27M | $26.21M | $20.03M | $16.52M | $16.36M | $35.66M | $17.67M | $17.79M | $12.28M | $11.81M | $8.06M | $- | $1.40M | $- |
| Long Term Debt | $9.74M | $10.03M | $10.29M | $10.55M | $11.51M | $11.85M | $922.00K | $1.04M | $1.15M | $1.25M | $1.36M | $1.04M | $- | $- | $- | $- | $12.65M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $2.48M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $173.72M | $- | $16.85M | $- |
| Total Non-Current Liabilities | $9.74M | $10.03M | $10.29M | $10.55M | $11.51M | $11.85M | $922.00K | $1.04M | $1.15M | $1.25M | $1.36M | $1.04M | $4.66M | $224.52M | $173.72M | $- | $29.50M | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-4.66M | $- | $- | $- | $- | $- |
| Total Liabilities | $22.52M | $22.33M | $28.40M | $25.08M | $33.77M | $38.06M | $20.96M | $17.55M | $17.50M | $36.91M | $19.03M | $18.83M | $12.28M | $236.33M | $181.78M | $- | $30.90M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $148.71M | $173.72M | $- | $- | $- |
| Common Stock | $7.00K | $7.00K | $7.00K | $7.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $6.00K | $5.00K | $5.00K | $5.00K | $- | $4.00K | $- | $- | $- |
| Retained Earnings | $-554.31M | $-524.96M | $-489.71M | $-457.76M | $-419.19M | $-372.43M | $-318.41M | $-265.16M | $-226.22M | $-191.01M | $-160.55M | $-140.53M | $-117.80M | $-100.03M | $-87.26M | $- | $-32.50M | $- |
| Accumulated Other Comprehensive Income Loss | $157.00K | $873.00K | $-248.00K | $-121.00K | $-50.00K | $-507.00K | $-710.00K | $-561.00K | $-1.12M | $-1.31M | $-1.29M | $-958.00K | $-58.00K | $17.00K | $-12.00K | $-30.65M | $- | $-4.13M |
| Other Total Stockholders Equity | $808.19M | $802.85M | $770.75M | $764.87M | $663.15M | $656.58M | $646.92M | $637.33M | $581.24M | $575.85M | $404.99M | $400.61M | $397.05M | $12.39M | $-162.31M | $- | $1.85M | $- |
| Total Stockholders Equity | $254.04M | $278.77M | $280.80M | $307.00M | $243.92M | $283.64M | $327.81M | $-265.16M | $-226.22M | $383.53M | $243.15M | $259.12M | $279.20M | $-87.62M | $-75.86M | $-30.65M | $-30.65M | $-4.13M |
| Total Equity | $254.04M | $278.77M | $280.80M | $307.00M | $243.92M | $283.64M | $327.81M | $-265.16M | $-226.22M | $383.53M | $243.15M | $259.12M | $279.20M | $-87.62M | $-75.86M | $-30.65M | $-30.65M | $-4.13M |
| Total Liabilities and Stockholders Equity | $276.56M | $301.10M | $309.19M | $332.08M | $277.69M | $321.70M | $348.76M | $-247.60M | $-208.72M | $420.44M | $262.19M | $277.95M | $291.48M | $148.71M | $105.92M | $-30.65M | $245.00K | $-4.13M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $276.56M | $301.10M | $309.19M | $332.08M | $277.69M | $321.70M | $348.76M | $-247.60M | $-208.72M | $420.44M | $262.19M | $277.95M | $291.48M | $148.71M | $105.92M | $-30.65M | $245.00K | $-4.13M |
| Total Investments | $225.68M | $213.06M | $239.75M | $161.66M | $200.64M | $244.21M | $280.54M | $313.25M | $291.79M | $149.15M | $213.01M | $231.46M | $215.93M | $72.97M | $- | $488.00K | $- | $618.00K |
| Total Debt | $10.79M | $11.04M | $11.27M | $11.49M | $12.51M | $12.33M | $1.36M | $1.46M | $1.56M | $1.65M | $1.75M | $1.32M | $- | $224.52M | $- | $- | $12.65M | $- |
| Net Debt | $-16.47M | $-50.73M | $-29.66M | $-130.40M | $-39.07M | $-44.28M | $-50.36M | $-62.21M | $-63.26M | $-261.62M | $-43.60M | $-40.37M | $-70.79M | $155.53M | $-102.79M | $244.00K | $12.40M | $309.00K |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-135.12M | $-192.96M | $-108.43M | $-83.75M | $-28.17M |
| Depreciation and Amortization | $1.35M | $941.00K | $470.00K | $30.00K | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $22.93M | $28.59M | $16.57M | $2.73M | $45.00K |
| Change in Working Capital | $-10.56M | $5.81M | $-5.16M | $4.02M | $812.00K |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.64M | $-745.00K | $1.61M | $2.44M | $591.00K |
| Other Working Capital | $-7.92M | $6.55M | $-6.77M | $1.57M | $221.00K |
| Other Non Cash Items | $-9.47M | $-8.89M | $-2.23M | $38.32M | $21.12M |
| Net Cash Provided by Operating Activities | $-130.87M | $-166.52M | $-98.77M | $-38.65M | $-6.20M |
| Investments in Property Plant and Equipment | $-241.00K | $-514.00K | $-275.00K | $-262.00K | $- |
| Acquisitions Net | $- | $- | $74.66K | $1.90M | $- |
| Purchases of Investments | $-283.65M | $-272.27M | $-347.24M | $-232.50M | $- |
| Sales Maturities of Investments | $268.38M | $373.73M | $272.58M | $16.50M | $- |
| Other Investing Activities | $- | $- | $-74.66K | $-216.00K | $- |
| Net Cash Used for Investing Activities | $-15.51M | $100.94M | $-74.93M | $-214.37M | $- |
| Debt Repayment | $- | $- | $- | $450.00K | $6.13M |
| Common Stock Issued | $95.05M | $48.41M | $165.40M | $158.81M | $2.00K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $27.07M | $4.92M | $2.37M | $164.29M | $2.00K |
| Net Cash Used Provided by Financing Activities | $122.11M | $53.33M | $167.77M | $323.55M | $6.13M |
| Effect of Forex Changes on Cash | $-55.00K | $-12.00K | $-42.00K | $11.00K | $- |
| Net Change in Cash | $-24.32M | $-12.27M | $-5.97M | $70.55M | $-65.00K |
| Cash at End of Period | $28.23M | $52.55M | $64.82M | $70.79M | $244.00K |
| Cash at Beginning of Period | $52.55M | $64.82M | $70.79M | $244.00K | $309.00K |
| Operating Cash Flow | $-130.87M | $-166.52M | $-98.77M | $-38.65M | $-6.20M |
| Capital Expenditure | $-241.00K | $-514.00K | $-275.00K | $-262.00K | $- |
| Free Cash Flow | $-131.11M | $-167.04M | $-99.05M | $-38.91M | $-6.20M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-29.35M | $-35.25M | $-31.95M | $-38.57M | $-46.75M | $-54.03M | $-53.25M | $-38.93M | $-35.21M | $-30.46M | $-20.02M | $-22.73M | $-17.77M | $-12.77M | $-15.56M | $-37.65M | $-16.70M | $-7.16M | $-2.16M | $-2.16M |
| Depreciation and Amortization | $315.00K | $309.00K | $316.00K | $408.00K | $403.00K | $265.00K | $139.00K | $134.00K | $150.00K | $127.00K | $103.00K | $90.00K | $16.00K | $9.00K | $4.00K | $1.00K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-10.54M | $- | $- | $- | $- | $- | $- | $- | $-11.06M | $11.07M | $-11.06M | $11.05M | $- | $- | $- | $- |
| Stock Based Compensation | $5.17M | $5.45M | $5.77M | $6.54M | $6.14M | $8.01M | $7.87M | $6.57M | $4.83M | $4.17M | $4.13M | $3.44M | $1.39M | $969.00K | $288.00K | $80.00K | $14.00K | $14.00K | $8.50K | $8.50K |
| Change in Working Capital | $2.70M | $-3.36M | $4.07M | $-13.97M | $-9.26M | $13.22M | $-1.55M | $3.39M | $-15.29M | $2.56M | $1.10M | $6.47M | $1.76M | $755.00K | $1.03M | $467.00K | $-461.00K | $341.00K | $254.00K | $254.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $824.00K | $-4.30M | $2.02M | $-1.19M | $-3.58M | $5.21M | $-2.28M | $-91.00K | $-8.26M | $8.71M | $2.95M | $-1.78M | $394.00K | $1.88M | $68.00K | $103.00K | $-341.00K | $508.00K | $- | $- |
| Other Working Capital | $1.87M | $935.00K | $2.05M | $-12.78M | $-5.67M | $8.02M | $733.00K | $91.00K | $-7.03M | $-6.14M | $-1.85M | $8.25M | $1.36M | $-1.12M | $967.00K | $364.00K | $-120.00K | $-167.00K | $254.00K | $254.00K |
| Other Non Cash Items | $-2.08M | $-2.61M | $1.64M | $6.51M | $8.34M | $-2.13M | $-2.49M | $-2.08M | $-1.73M | $-386.00K | $2.84M | $5.41M | $10.96M | $-11.05M | $15.38M | $23.03M | $15.26M | $4.92M | $683.00K | $683.00K |
| Net Cash Provided by Operating Activities | $-23.25M | $-35.46M | $-24.54M | $-47.62M | $-51.66M | $-34.66M | $-49.28M | $-30.92M | $-47.26M | $-23.99M | $-14.79M | $-12.73M | $-14.70M | $-11.02M | $-9.91M | $-3.02M | $-1.89M | $-1.88M | $-1.21M | $-1.21M |
| Investments in Property Plant and Equipment | $-6.00K | $- | $-60.00K | $-175.00K | $-211.00K | $-48.00K | $-195.00K | $-60.00K | $-112.00K | $-97.00K | $-28.00K | $-38.00K | $-48.00K | $-203.00K | $-11.00K | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $-46.34K | $-38.94K | $-35.01K | $18.84K | $1.22M | $-64.26K | $- | $- | $- | $- | $- | $1.90M | $- | $- | $- | $- |
| Purchases of Investments | $-75.24M | $-32.25M | $-150.71M | $-25.45M | $-28.66M | $-70.79M | $-63.99M | $-108.83M | $-204.73M | $-17.11M | $-56.72M | $-68.67M | $-159.54M | $-72.96M | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $64.25M | $61.50M | $75.25M | $67.39M | $75.00M | $109.72M | $99.00M | $90.00M | $64.00M | $81.37M | $75.00M | $52.21M | $-216.00M | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $-75.46M | $41.94M | $46.34K | $38.94K | $35.01K | $-18.84K | $-1.22M | $64.26K | $18.28M | $-16.46M | $232.50M | $-72.96M | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $-11.00M | $29.25M | $-75.52M | $41.77M | $46.12M | $38.89M | $34.82M | $-18.89M | $-140.84M | $64.16M | $18.25M | $-16.50M | $-143.09M | $-73.16M | $-11.00K | $1.90M | $- | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $450.00K | $2.08M | $1.90M | $- | $- |
| Common Stock Issued | $- | $-232.00K | $-906.00K | $96.09M | $585.00K | $1.62M | $-47.00K | $48.45M | $-10.24M | $176.53M | $134.00K | $86.00K | $164.22M | $- | $- | $56.41M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $1.02M | $-906.00K | $- | $250.00K | $- | $- | $- | $-10.36M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-25.00K | $26.86M | $140.00K | $92.00K | $585.00K | $1.62M | $2.47M | $191.00K | $777.00K | $1.26M | $249.00K | $86.00K | $159.58M | $50.38M | $56.73M | $56.41M | $2.00K | $- | $1.07M | $1.07M |
| Net Cash Used Provided by Financing Activities | $-25.00K | $26.86M | $-906.00K | $96.18M | $585.00K | $1.62M | $2.47M | $48.65M | $-10.36M | $177.79M | $249.00K | $86.00K | $159.58M | $50.38M | $56.73M | $56.87M | $2.08M | $1.90M | $1.07M | $1.07M |
| Effect of Forex Changes on Cash | $-233.00K | $192.00K | $-9.00K | $-5.00K | $-86.00K | $16.00K | $38.00K | $20.00K | $8.00K | $-38.00K | $-54.00K | $42.00K | $11.00K | $23.00K | $-2.00K | $2.00K | $- | $- | $- | $- |
| Net Change in Cash | $-34.51M | $20.84M | $-100.97M | $90.32M | $-5.03M | $5.87M | $-11.95M | $-1.15M | $-198.45M | $217.93M | $3.65M | $-29.10M | $1.80M | $-33.80M | $46.80M | $55.75M | $192.00K | $18.00K | $-137.50K | $-137.50K |
| Cash at End of Period | $28.23M | $62.74M | $40.92M | $141.90M | $51.58M | $57.59M | $51.72M | $63.67M | $64.82M | $263.27M | $45.34M | $41.69M | $70.79M | $68.99M | $102.79M | $55.99M | $244.00K | $52.00K | $34.00K | $-137.50K |
| Cash at Beginning of Period | $62.74M | $41.90M | $141.90M | $51.58M | $56.61M | $51.72M | $63.67M | $64.82M | $263.27M | $45.34M | $41.69M | $70.79M | $68.99M | $102.79M | $55.99M | $244.00K | $52.00K | $34.00K | $171.50K | $- |
| Operating Cash Flow | $-23.25M | $-35.46M | $-24.54M | $-47.62M | $-51.66M | $-34.66M | $-49.28M | $-30.92M | $-47.26M | $-23.99M | $-14.79M | $-12.73M | $-14.70M | $-11.02M | $-9.91M | $-3.02M | $-1.89M | $-1.88M | $-1.21M | $-1.21M |
| Capital Expenditure | $-6.00K | $- | $-60.00K | $-175.00K | $-211.00K | $-48.00K | $-195.00K | $-60.00K | $-112.00K | $-97.00K | $-28.00K | $-38.00K | $-48.00K | $-203.00K | $-11.00K | $- | $- | $- | $- | $- |
| Free Cash Flow | $-23.25M | $-35.46M | $-24.60M | $-47.80M | $-51.87M | $-34.71M | $-49.48M | $-30.98M | $-47.38M | $-24.09M | $-14.82M | $-12.76M | $-14.75M | $-11.22M | $-9.93M | $-3.02M | $-1.89M | $-1.88M | $-1.21M | $-1.21M |
Ventyx Biosciences Dividends
Explore Ventyx Biosciences's dividend history, including dividend yield, payout ratio, and historical payments.
Ventyx Biosciences News
Read the latest news about Ventyx Biosciences, including recent articles, headlines, and updates.
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer.
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.
Ventyx Biosciences Announces Departure of Chief Financial Officer
SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (NASDAQ:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX SHAREHOLDER ALERT: BFA Law is Investigating the Ventyx (Nasdaq:VTYX) Board for Trading on Inside Information to Avoid Losses, Contact the Firm for Details
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX INVESTOR ALERT: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for VTYX.